Plasmatic MicroRNAs and Treatment Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer: A Hospital-Based Cohort Study and In Silico Analysis

Prostate cancer (PCa) is one of the most common malignancies among men worldwide. Inevitably, all advanced PCa patients develop metastatic castration-resistant prostate cancer (mCRPC), an aggressive phase of the disease. Treating mCRPC is challenging, and prognostic tools are needed for disease mana...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-05, Vol.24 (10), p.9101
Main Authors: Silva, Jani, Tavares, Valéria, Afonso, Ana, Garcia, Juliana, Cerqueira, Fátima, Medeiros, Rui
Format: Article
Language:English
Subjects:
abiraterone acetate
Abiraterone Acetate - therapeutic use
Acetic acid
Analysis
Androgen receptors
Androgens
Angiogenesis
Asymptomatic
Biomarkers
Biopsy
Cancer
Cancer therapies
Care and treatment
Castration
Cell cycle
Chemotherapy
Clinical outcomes
Cohort analysis
Cohort Studies
Deregulation
enzalutamide
Enzymes
Epigenetics
Humans
Life expectancy
liquid biopsy
Male
Malignancy
Metastases
Metastasis
MicroRNA
MicroRNAs
MicroRNAs - genetics
MicroRNAs - therapeutic use
miRNA
Nitriles - therapeutic use
Oncology, Experimental
Patient outcomes
Patients
Physiological aspects
prognosis
Prostate cancer
prostatic neoplasms
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - genetics
Radiation therapy
Retrospective Studies
Risk assessment
Survival
Testosterone
Therapeutic targets
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prostate cancer (PCa) is one of the most common malignancies among men worldwide. Inevitably, all advanced PCa patients develop metastatic castration-resistant prostate cancer (mCRPC), an aggressive phase of the disease. Treating mCRPC is challenging, and prognostic tools are needed for disease management. MicroRNA (miRNA) deregulation has been reported in PCa, constituting potential non-invasive prognostic biomarkers. As such, this study aimed to evaluate the prognostic potential of nine miRNAs in the liquid biopsies (plasma) of mCRPC patients treated with second-generation androgen receptor axis-targeted (ARAT) agents, abiraterone acetate (AbA) and enzalutamide (ENZ). Low expression levels of miR-16-5p and miR-145-5p in mCRPC patients treated with AbA were significantly associated with lower progression-free survival (PFS). The two miRNAs were the only predictors of the risk of disease progression in AbA-stratified analyses. Low miR-20a-5p levels in mCRPC patients with Gleason scores of
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms24109101